-+ 0.00%
-+ 0.00%
-+ 0.00%

Barclays Maintains Equal-Weight on Pacific Biosciences, Lowers Price Target to $1.5

Benzinga·06/25/2025 13:56:53
Listen to the news
Barclays analyst Luke Sergott maintains Pacific Biosciences (NASDAQ:PACB) with a Equal-Weight and lowers the price target from $2 to $1.5.